Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant by Ittipat Meewan (7455041)

“…In protease assays, <b>22</b> had a comparable inhibition profile for the common mutant HCV GT1b D168A and the wild-type enzyme. …”

Decrease in cell viability by siRNA and miRNA dependent induction of DTA. by Liraz Harel (675561)

“…<p>U251 cells were transfected with the indicated construct (50 ng) with (A) or without (B) siRNAs (10pmol). …”

Effects of bFGF on decrease of HG-induced accumulation of intracellular ROS levels. by Yuan Hu Xuan (632639)

Old rat serum present higher levels of pro-inflammatory cytokine. by María Paz Saldías (4430032)

Orsay virus infection of the <i>lin-8(n2731</i>) synMuv A mutant induces a Muv phenotype indicative of decreased synMuv B gene activity, and 2 different synMuv B mutants produce 50–100× less Orsay virus RNA. by Ashwin Seetharaman (615458)

SmedCB shows a transient spike of protease activity following digestion and amputation, while chemical inhibition of both cathepsin B and L leads to a significant decrease in regen... by Louise S. Goupil (2922159)

“…<b>(C)</b> Worms treated with SmedCB dsRNA did not show any significant defects in regeneration compared to untreated controls, but treatment with K11777 <b>(D)</b> showed a highly significant decrease in growth compared to vehicle worms. …”

Decrease in intracellular lipid accumulation in 3T3-L1 cells by baicalein. by Yukari Nakao (3138795)

Tempol and L-NAME help prevent the decrease in F_max. by Travis L. Dutka (321984)

Cellular uptake of [¹⁴C]docosahexaenoic acid (DHA) by RBECs transfected with MFSD2A siRNA. by Takuro Iwao (14636741)

Activation of AKT, decrease in FOXO and activation of glycolytic genes in CERT heterozygous mice. by Niraj K. Nirala (424266)

“…(D). A simple graphical model depicting metabolic reprogramming in <i>dcerk¹</i> due to increased AKT activation and decreased FOXO to maintain energy balance. …”

Apicoplast inhibitors decrease global parasite prenylation in the second IDC after treatment. by Kit Kennedy (4915510)

Cholecalciferol decreases inflammation and improves vitamin D regulatory enzymes in lymphocytes in the uremic environment: A randomized controlled pilot trial - Fig 4 by José Tarcisio G. Carvalho (4217248)

Subjects:

Influence of ghrelin treatment (0.5 μg/g BW, twice a day, intraperitoneal (ip.)) on oxidative burst capacity of neutrophils after cecal ligation and puncture (CLP)-induced sepsis. by Daniel Siegl (717509)

Influence of ghrelin treatment (0.5 μg/g BW, twice a day, intraperitoneal (ip.)) on peritoneal cellular immune response after cecal ligation and puncture (CLP)-induced sepsis. by Daniel Siegl (717509)

Terpenoids decrease single-channel activity of L-AChRs elicited by ACh. by Guillermina Hernando (553795)

Cell-penetrating 15mer peptides decrease the proliferation and viability of cancer cells. by Pavan Kumar Puvvula (10495853)

The GluN2B-C456Y mutation decreases recombinant NMDAR currents and alters receptor properties. by Wangyong Shin (6793040)

“…<p>(A) The GluN2B-C456Y mutation strongly decreases diheteromeric GluN1/GluN2B NMDAR currents in <i>Xenopus</i> oocytes. …”

Thimerosal decreases the expression of survivin via the PI3K/Akt pathway. by Wen-Xue Li (189757)

HoxA9-ER directly represses <i>Cebpa</i> gene expression in myeloid cells. by Lei Peng (260321)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”